New York State Teachers Retirement System Decreases Holdings in Edwards Lifesciences Co. (NYSE:EW)

New York State Teachers Retirement System cut its position in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 8.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 482,645 shares of the medical research company's stock after selling 42,203 shares during the period. New York State Teachers Retirement System owned approximately 0.08% of Edwards Lifesciences worth $35,730,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Wellington Management Group LLP grew its stake in shares of Edwards Lifesciences by 86.3% in the third quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company's stock worth $2,080,845,000 after acquiring an additional 14,610,123 shares during the period. Jennison Associates LLC purchased a new stake in Edwards Lifesciences during the fourth quarter valued at $555,939,000. Assenagon Asset Management S.A. grew its stake in shares of Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company's stock valued at $314,182,000 after purchasing an additional 3,506,886 shares during the period. Jacobs Levy Equity Management Inc. increased its position in shares of Edwards Lifesciences by 239.9% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 3,693,663 shares of the medical research company's stock valued at $243,745,000 after purchasing an additional 2,606,950 shares during the last quarter. Finally, Seilern Investment Management Ltd bought a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $109,490,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 6,500 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the transaction, the vice president now owns 46,936 shares of the company's stock, valued at $3,555,402. The trade was a 12.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 500 shares of Edwards Lifesciences stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the completion of the transaction, the vice president now owns 23,189 shares in the company, valued at $1,594,475.64. This represents a 2.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 26,489 shares of company stock worth $2,002,829 in the last ninety days. 1.27% of the stock is owned by company insiders.

Edwards Lifesciences Trading Down 1.2 %

Shares of EW stock traded down $0.95 during trading hours on Wednesday, reaching $74.73. 3,023,259 shares of the stock were exchanged, compared to its average volume of 4,526,352. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $44.07 billion, a price-to-earnings ratio of 10.72, a price-to-earnings-growth ratio of 4.92 and a beta of 1.10. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $96.12. The company's 50-day moving average price is $72.82 and its 200-day moving average price is $69.79.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts' consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the company. Wolfe Research cut Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Robert W. Baird dropped their price target on shares of Edwards Lifesciences from $73.00 to $68.00 and set a "neutral" rating for the company in a research report on Friday, October 25th. JPMorgan Chase & Co. increased their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a "neutral" rating in a research note on Friday, October 25th. Evercore ISI cut their target price on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Finally, Stifel Nicolaus raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and increased their price objective for the company from $75.00 to $90.00 in a report on Thursday, January 30th. One equities research analyst has rated the stock with a sell rating, fourteen have given a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $79.95.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.